Vanda Pharmaceuticals (VNDA) Share-based Compensation (2010 - 2026)

Vanda Pharmaceuticals has reported Share-based Compensation for 16 years, with the latest figure at $915000.0 in Q1 2025.

• Quarterly Share-based Compensation fell 74.47% year-over-year to $915000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $915000.0 (changed N/A YoY) and the FY2025 annual result came in at $915000.0, changed N/A from the prior year.
• Share-based Compensation rose to $915000.0 in Q1 2025 per VNDA's latest filing, from -$6.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $4.8 million in Q1 2022 and troughed at -$10.8 million in Q4 2023.
• A 5-year average of $2.0 million and a median of $3.8 million in 2021 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2021 and 2023: Share-based Compensation rose 26.03% in 2021, then slumped 384.62% in 2023.
• Over 5 years, Share-based Compensation stood at $3.8 million in 2021, then increased by 0.24% to $3.8 million in 2022, then plunged by 384.62% to -$10.8 million in 2023, then soared by 38.98% to -$6.6 million in 2024, then surged by 113.93% to $915000.0 in 2025.
• According to Business Quant data, Share-based Compensation over the past three periods registered $915000.0, -$6.6 million, and $3.0 million for Q1 2025, Q3 2024, and Q2 2024 respectively.